Ovid Therapeutics Stock Forecast, Price & News

-0.03 (-0.80 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume280,263 shs
Average Volume340,584 shs
Market Capitalization$252.93 million
P/E Ratio2.49
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Ovid Therapeutics logo

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.94 out of 5 stars

Medical Sector

338th out of 2,222 stocks

Pharmaceutical Preparations Industry

170th out of 869 stocks

Analyst Opinion: 3.2Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

Is Ovid Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ovid Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View analyst ratings for Ovid Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Ovid Therapeutics?

Wall Street analysts have given Ovid Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ovid Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 1,670,000 shares, a decrease of 52.6% from the June 15th total of 3,520,000 shares. Based on an average trading volume of 838,300 shares, the short-interest ratio is currently 2.0 days. Approximately 3.1% of the shares of the company are sold short.
View Ovid Therapeutics' Short Interest

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Ovid Therapeutics

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its earnings results on Thursday, May, 13th. The company reported $2.53 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.45 by $1.08. The company had revenue of $208.38 million for the quarter, compared to analyst estimates of $2.21 million.
View Ovid Therapeutics' earnings history

How has Ovid Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 39.2% and is now trading at $3.73.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OVID?

8 Wall Street analysts have issued 1-year price targets for Ovid Therapeutics' stock. Their forecasts range from $4.00 to $40.00. On average, they expect Ovid Therapeutics' stock price to reach $11.83 in the next year. This suggests a possible upside of 217.2% from the stock's current price.
View analysts' price targets for Ovid Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir, Chairman & CEO (Age 68, Pay $861.24k)
  • Mr. Jeffrey A. Rona, Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer (Age 53, Pay $494.5k)
  • Mr. Thomas Michael Perone J.D., M.B.A., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 56, Pay $633.37k)
  • Dr. Amit Rakhit, Pres & Chief Medical Officer (Age 51)
  • Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP, Founder & Member of Scientific Advisory Board (Age 64)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR
  • Ms. Suzanne K. Wakamoto SPHR, SHRM-SCP, Sr. VP of HR
  • Dr. Dirk Haasner, Sr. VP of Global Manufacturing & CMC QA (Age 56)
  • Dr. Claude Nicaise, Head of Rare Disease Strategy (Age 68)
  • Mr. Jason Tardio M.B.A., Chief Commercial Officer (Age 44)

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $3.73.

How much money does Ovid Therapeutics make?

Ovid Therapeutics has a market capitalization of $252.93 million and generates $12.62 million in revenue each year. The company earns $-81,040,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics employs 64 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is

Where are Ovid Therapeutics' headquarters?

Ovid Therapeutics is headquartered at 1460 Broadway Suite 15044, New York NY, 10036.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.